Index: *Infertility*

abdominal hysterectomy 45
abdominal myomectomy 32–3
acardiac twinning 147
acetylsalicylic acid 68, 69
acromegaly 94–6, 101
diagnosis 95
presenting signs and symptoms 94–5
treatment 95–6
acute respiratory distress syndrome (ARDS) 124, 148
adnexal torsion 149
adoption 179–80
adrenal disorders 99–100, 101
American College of Obstetricians and Gynecologists (ACOG) 1
diagnosis 95
presenting signs and symptoms 94–5
treatment 95–6
American Fertility Society 34
American Society for Reproductive Medicine (ASRM) 1
diagnosis 95
presenting signs and symptoms 94–5
treatment 95–6
American Urologic Association 16
American Society for Reproductive Medicine (ASRM) 1
diagnosis 95
presenting signs and symptoms 94–5
treatment 95–6
amniocentesis 158
amenorrhea 48
exercise and/or weight loss as cause 48, 49
ovulation induction 107
polycystic ovary syndrome 51
American College of Obstetricians and Gynecologists (ACOG) 1
diet 2
HIV infection 120
pelvic inflammatory disease 20
smoking 4
American Fertility Society 34
American Society for Reproductive Medicine (ASRM) 1
diagnosis 95
presenting signs and symptoms 94–5
treatment 95–6
American Urologic Association 16
American Society for Reproductive Medicine (ASRM) 1
diagnosis 95
presenting signs and symptoms 94–5
treatment 95–6
Aneuploidy and infertility 34–5, 36
adnexal torsion 149
adoption 179–80
adrenal disorders 99–100, 101
adult respiratory distress syndrome (ARDS) 124, 148
age 3
epidemiology of 124
ovarian reserve, diminished 67, 69
fertility preservation 164, 172
FSH values 14, 15
intrauterine insemination 123
menstrual irregularities 14–15
ovarian reserve 3, 13–14, 59–60
ovulation induction 54–7
ovulation induction see ovulation induction
polycystic ovary syndrome 52
polycystic ovary syndrome 50, 51
smoking 3
American Urologic Association 16
analgesics, endometriosis 42–3
anaphylaxis, and intrauterine insemination 123
anastrozole adverse effects and safety concerns 110–11
dose, optimal 110
endometriosis treatment 44
ovulation induction 108, 110
polycystic ovary syndrome 56
androgen insensitivity syndrome 53–4
androgens
aromatase inhibitors, mechanism of action 109
male infertility 74
ovarian reserve, diminished 67, 69
aneuploidy following oocyte cryopreservation 167
screening 159–60, 162
Angelman syndrome (AS) 152
anorexia nervosa 49, 100
anovulation 48
classification 48, 49, 104
diagnosis 48–54
ovulation induction see ovulation induction
treatment 54–7
antagonist protocol, IVF 66
antimüllerian hormone (AMH) evaluation 14, 15
ovarian reserve, diminished 62
ovulation, physiological basis of 102
polycystic ovary syndrome 52
antiphospholipid antibody syndrome 136
antisperm antibodies (ASA) 118
antral follicle count (AFC) 15
age factors 3
ovarian failure, premature 50
ovarian reserve, diminished 62–3
polycystic ovary syndrome 52
unexplained infertility 85
aromatase inhibitors (AIs) 108
adverse effects and safety concerns 110–11

birth defects, risk of 111
breast cancer 111–12, 165, 166
dose, optimal 110
endometriosis 44
fertility preservation 165, 166
indications 109–10
intrauterine insemination 117
ovarian reserve, diminished 68, 69
ovulation induction 108–12
peripheral mechanism of action 109
pharmacokinetics 108
polycystic ovary syndrome 56, 109
pregnancy outcome 111
array comparative genome hybridization (aCGH) 160
Asherman syndrome 34–5
aspirin 68, 69
Australia 176, 177, 178
Austria 179
autoimmunity against sperm 77
autotransplantation of ovarian tissue 168–9
availability of infertility treatment 176–7
azoospermia 71
chromosomal abnormalities 74
 treatment 74–5, 77, 79–81
bariatric surgery 2
basal antral follicular count (BAFC) 3
basal body temperature (BBT) charting 9–10, 84
basal estradiol levels 61–2
basal FSH levels 14, 15, 61
Beckwith—Wiedemann syndrome (BWS) 152
Belgium 178, 180
beta-blockers 97
bicorunate uterus 29–30, 36
bilateral salpingoophorectomy 45
birth defects 111, 124
blastocyst biopsy 161
blastocyst development, IVF 131–2
blastomere biopsy 155–6, 157
bleeding
after egg retrieval 151
after intrauterine insemination 123
blood transfusion, and multiple pregnancy 146
body mass index (BMI)
as factor affecting fertility 1, 2, 5
as factor affecting menstrual cycles 54
body temperature charting 9–10, 84
bowel injuries caused by egg retrieval 151
breast cancer 153
aromatase inhibitors for IVF 111–12
fertility preservation 165–6, 172
ovarian stimulation 165–6
preimplantation genetic diagnosis 160–1
bromocriptine 57, 74, 93
bulimia nervosa 49
CA-125 40–1, 85
cabergoline 57, 93, 95
caffeine 4, 5, 6, 86
CAGE questionnaire 5
Canada 176, 177–8, 179, 180
cancer
fertility preservation see fertility preservation
risk in the mother 153
 see also specific cancers
carbimazole 97
cardiocystic disease 53
Centers for Disease Control and Prevention (CDC) 120, 135, 141, 146
cerebral palsy 146
cervical cancer 153, 171
cervical evaluation 13
cervical factor infertility, and intrauterine insemination 114, 115
chemoperturbation, laparoscopic 18, 19, 20
chemotherapy, and fertility preservation 164, 165, 171–2, 173
child, long-term complications in the 152–3
chlamydia serology 12, 21–2, 84
chlorpheniramine 76
chromoperturbation 85, 116
chromosomal abnormalities
male infertility 74
ovulatory disorders 53–4
preimplantation genetic diagnosis 158–9
chronic autoimmune thyroiditis 98
clofemphene citrate (CC) 55, 105
adverse effects and risks 107–8, 111, 150
cancer 153
challenge test (CCCT) 14, 15, 62
endometriosis 46
indications 106
intrauterine insemination 116–18
male infertility 74
mechanism of action 105–6
outcome of treatment 106–7, 108
ovarian reserve, diminished 68–9
pharmacokinetics 105
polycystic ovary syndrome 54–5
regimens 106
unexplained infertility 87
coelomic metaplasia theory, endometriosis 38–9
coffee see caffeine
comparative genome hybridization (CGH) 160, 161
complications of infertility treatment 146, 147, 153
acute
medication-related 146–50
procedure-related 151
long-term
in child 152–3
in mother 153
pregnancy 151–2
congenital adrenal hyperplasia (CAH) 99, 100, 101
congenital malformations 152
consent see informed consent
controlled ovarian hyperstimulation see ovulation induction
corticosteroids 66–7, 69, 77
cortisol 99–100
counseling
egg donation 138–9
fertility preservation 172, 173
preconceptual
congenital adrenal hyperplasia 100
hyperthyroidism 97–8
intrauterine insemination 117
ovulation induction 117
uterine abnormalities 12
preimplantation genetic diagnosis 155
cranioopharyngioma 49
Croatia 178
cryopreservation
ovarian tissue 165, 168–70, 172, 173
sperm 76, 80
whole ovaries 170–1, 173
see also under embryo; oocytes
cryptorchidism 72
Cushing disease 99, 100
Cushing syndrome 99–100, 101
cystic fibrosis
egg donation 138
preimplantation genetic diagnosis 156, 161
transmembrane conductance regulator gene testing 74
cyst rupture 150
danazol 43–4
dep deep venous thrombosis (DVT) 148
dehydroepiandrosterone (DHEA) 67–8, 69
Denmark 179
density gradients, sperm selection by 119, 128
Department of Health and Human Services, USA 181
depression, clinical 100
developmental origin of health and disease (DOHaD) hypothesis 152
dexamethasone 67, 69
DEXA scans 92
DHEA (dehydroepiandrosterone) 67–8, 69
diabetes
ejaculatory failure 76
gestational 146, 148, 152
didelphys uterus 29–30, 36
diet 2, 6, 86
diminished ovarian reserve see ovarian reserve: diminished
direct intraperitoneal insemination (DIPI) 121–2
DNA damage testing 74
DNA methylation 153
dopamine agonists 93, 94, 95
Doppler ultrasound of the testis 80
dual-energy X-ray absorptiometry (DEXA) scans 92
dyslipidemia 53
eating disorders 49, 100
eyectopic pregnancy 148–9
egg and embryo donation 135, 144
clinical results 141–2
cycle management 139–41
recipients 135–7
regulations 179
egg retrieval, complications 151
egg sharing 143
ejaculatory disorders 76, 115–16
electroejaculation 76, 116
embryo assessment, IVF 131–2
biopsy 155–6, 157
cryopreservation 132–4
fertility preservation 164–6, 172
preimplantation genetic diagnosis 156
regulation 178–9
culture, IVF 130–1
development 131
donation see egg and embryo donation
mosaicism 161
rights of the 178–9
transfer (ET)
endometriosis 46, 47
IVF 132
multiple gestation risk 146
polycystic ovary syndrome 57
regulation 180–1
tubal surgery versus 23–4
vitrification 161
embryonic rest theory, endometriosis 39
emotional lability 150
empiric infertility treatment 175
enclomiphene 105
endocrine disorders 101
acromegaly 94–6
adrenal disorders 99–100
hyperprolactinaemia and prolactinomas 90–4
male infertility 72–3
pituitary disorders 90
thyroid disorders 96–9
endometrial biopsy 10
endometrial cancer 153
endometrial hyperplasia 34
endometrial polyps 11, 12, 33–4, 36
endometrial thickness 107–8
endometriosis 38, 46–7
clinical presentation 38
diagnosis 40–1
imaging techniques 41–2
intruterine insemination 116, 125
and male infertility 78
pathogenesis 38–40
treatment 42–6
epigenetic regulation of gene expression 152–3
erectile dysfunction 115
estradiol
age factors 3, 14
ovarian reserve, diminished 61–2
ovulation, physiological basis of 103
estrogen
egg donation 140, 141
ovulation, physiological basis of 103, 104
ethical issues
egg and embryo donation 142–4
egg sharing 143
preimplantation genetic diagnosis 160–1, 162
Europe, infertility treatment in 181
outcome monitoring and success rates 181
regulation 178–9, 180, 181
reimbursement 177–8
utilization and availability 176, 177
European IVF Monitoring Programme (EIM) 181
European Society of Human Reproduction and Embryology (ESHRE)
outcome monitoring, infertility treatment 181
polycystic ovary syndrome 50, 51
preimplantation genetic diagnosis 155, 161
reimbursement of infertility treatment 177–8
social sexing 161
European Society of Hysteroscopy 32
evaluation of the infertile couple 8, 9, 16–17
egg donation 136–7
female 8–15
intrauterine insemination 116
male 15–16, 71–4
unexplained infertility 83–5
exemestane 108
exercise
to improve fertility 2, 6, 54
ovulatory disorders resulting
from 48–9, 51
exogenous FSH ovarian reserve
test (EFORT) 14, 15
expectant management of
unexplained infertility 86, 88
factors affecting fertility 1, 5–6
age 2–3, 5
alcohol 4–5, 6
caffeine 4, 5
smoking 3–4, 5
weight 1–2, 5
failed amplification (FA),
preimplantation genetic
diagnosis 157–8
fallopian tubes
anatomy 21
assessment 10–12, 18
unexplained infertility 84–5
tubal factor infertility 18–19, 24
diagnosis 19–22
management 22–3

tubal surgery versus IVF and
embryo transfer 23–4
see also tubal entries
fallopian tube sperm perfusion
(FSP) 122
falloposcopy (salpingoscopy) 12, 21
family balancing 161
fecundability, definition 1
fertility preservation 164, 173
embryo cryopreservation 164–6
individualization 172–3
logistics 173
medical approach 171–2
oocyte cryopreservation 165, 166–8
ovarian tissue

cryopreservation 165,
168–70
surgical approach 171
whole ovaries, cryopreservation
of 170–1
fibroids, uterine 11, 12
fimbrioplasty 23
financial issues
egg donation 137, 141, 142, 179
egg sharing 143
international
comparisons 176–8, 179
fine-needle aspiration (FNA),
sperm recovery 80
Finland 176, 180
“flare” IVF protocol 65–6
fluorescent in-situ hybridization
(FISH) 158, 159, 162
folic acid supplementation 2, 6, 86
follicle stimulating hormone (FSH)
age factors 3
basal levels 14, 15, 61
elevations 15
evaluation 14–15
fertility preservation 166
ovulation
induction 104–6, 107, 109,
110, 111, 112
physiological basis of 102–3,
104
unexplained fertility 85
Food and Drug Administration
(FDA)
gamete donation 137, 138, 179
letrozole 56
metformin 55
France 179, 181
gamma knife radiosurgery 94, 96
ganirelix acetate 140
gay couples 135, 144, 180
gender selection 161, 162
genetic screening and testing
genital adrenal hyperplasia 100
egg donation 138
men 16, 73
see also preimplantation genetic
diagnosis; preimplantation
genetic screening
Germany 178, 179, 180, 181
gestational carrier surrogacy 135,
144, 179–80
gestational diabetes 146, 148, 152
glass wool filtration sperm washing
technique 119
gonadotropin-releasing hormone
(GnRH) stimulation test 62
gonadotropin-releasing hormone
(GnRH) analogues
adenomysis 35
anovulation 54, 56
egg donation 140
endometriosis 44, 45, 46
fertility preservation 171–2, 173
intrauterine
insemination 117–18
myomas, uterine 31–2
ovarian reserve,
diminished 63–5, 66
polycystic ovary syndrome 56
gonadotropins
injectable see injectable
gonadotropin preparations
male infertility 74
Graves disease 96, 97
Greece 176, 179
growth discordance, monozygotic
twinning 147
growth hormone (GH)
acromegaly 94, 95, 96
IVF 65, 67, 69
ovarian reserve, diminished 65,
67, 69
pituitary tumors 91
Hashimoto’s thyroiditis 98
Health Insurance Portability and
Accountability Act (HIPAA),
USA 143–4
heart failure, and multiple
pregnancy 146
hepatitis B and C 120
HEPES 127–8, 129, 130
HEPES-buffered human tubal fluid
(HTF) medium 128, 129, 130
heterotopic pregnancy 149
heterotopic transplantation of
ovarian tissue 169
high gonadotropin dose protocol,
IVF 64
hirsutism 51
histone modification 153
history taking 8–9, 72
egg donation 138
unexplained infertility 83–4
HIV 120
HLA typing 158, 161
Hodgkin lymphoma 168, 171
“hook effect”, prolactin-secreting
tumors 92
hormonal testing 9
human chorionic gonadotropin
(hCG)
oviductal hyperstimulation
syndrome 147
ovarian reserve, diminished 63
ovulation
induction 105, 117
physiological basis of 104
Human Genome Project 161
human immunodeficiency virus
(HIV) 120
Huntington's disease 161
hydrosalpinges 11, 22–3, 24
hydrosalphinx fluid, drainage of 23
17-hydroxyprogesterone 100
hyperandrogenism 51
hypercortisolemia 99–100
hyperprolactinaemia 48, 49, 51, 90, 101
acromegaly 96
brain imaging 91–2
causes 91
in pregnancy 94
presenting symptoms 90–1
screening 91
therapy 57, 92–4
hyperthyroidism 96
diagnosis 97
presenting symptoms 96–7
treatment 97–8
hypogonadotropic hypogonadism
females 48–9, 91
males 75–6, 91
hypo-osmotic swelling test 79
hypophysectomy 49
hypopituitarism 91
hypospadias 116
hypospermatogenesis 80
hypothalamic anovulation 48–9
hypothyroidism 96, 101
causes 98
diagnosis 98–9
presenting symptoms 98
preoperative treatment 99
hysterectomy 45, 146
hysterosalpingo-contrast
sonography (HyCoSy) 12, 20
hysterosalpingography (HSG) 9
contraindications 13
fallopian tube
assessment 10–12, 19–20, 84–5
pelvic peritoneum evaluation 13
polyps, endometrial 33
preoperative 20–1
rotation during 20
tubal factor infertility 19–20, 84–5
unexplained infertility 84–5
uterus evaluation 12, 27
hysteroscopic adhesiolysis 34
hysteroscopic metroplasty 29, 36
hysteroscopic myomectomy 32
hysteroscopy 27, 34
Iceland 176
identification errors, intrauterine
insemination 123–4
IGF-1 94, 95, 96
implantation 26
window 139–40, 141
imprinting 152–3
India 179, 180
induction theory, menstruation 39
infant mortality rates 176
infections
egg donation 138
following egg retrieval 151
intrauterine insemination 120,
123
infertility, definition 1, 8, 175
inflammatory markers, polycystic
ovary syndrome 53
informed consent
egg donation 138–9
oocyte cryopreservation 167,
168, 173
surrogacy 144
inhibin B
evaluation 14
male infertility 80
ovarian reserve, diminished 62
injectable gonadotropin
preparations 104–5, 117
institutional review boards (IRBs),
and oocyte cryopreservation 167, 168,
173
insulin-like growth factor-1
(IGF-1) 94, 95, 96
insulin resistance 52–3
insulin-sensitizing agents 55–6
international perspective on
infertility treatment 175–6, 181–2
outcome monitoring and
success rates 181
regulation 178–81
reimbursement 177–8
utilization and availability 176–7
interstitial pregnancy 148
intracranial insemination (ICI) 121
intracytoplasmic sperm injection
(ICSI)
complications 151
IVF 129–30
male infertility 75, 78–9, 80, 81
oocyte cryopreservation 166, 167
polycystic ovary syndrome 55–6,
57
preimplantation genetic
diagnosis 156
unexplained infertility 88
intrafollicular insemination 122
intrauterine adhesions (IUA) 34–5,
36
intrauterine growth retardation
(IUGR) 152
intrauterine insemination
(IUI) 114, 125–6
aromatase inhibitors 110, 111,
112
comparison with other forms of
artificial
insemination 121–2
contraindications 116
endometriosis 46
with hormonal stimulation 87,
88, 116–18
indications 114–16
infection transmission 120
male infertility 75, 78, 81
natural cycles versus controlled
ovarian hyperstimulation 116–18
outcomes, benefits, and
limits 125
polycystic ovary syndrome 57
polyps, endometrial 33
procedure 120
protocols 121
risks and complications 122–5
semen parameters and
processing 118–19
timed intercourse 86
unexplained infertility 87, 88
work-up before 116
intrauterine tuboperitoneal
insemination 122
in vitro fertilization (IVF) 127, 134
age factors 3
alcohol consumption 5
aromatase inhibitors 111–12
body mass index 2
breast cancer patients 111–12
caffeine consumption 4
donor (DIF) 135–44
ectopic pregnancy 148
egg sharing 143
embryo assessment 131–2
embryo freezing 132–4
endometriosis 46, 47
international comparison 177, 180
and intracytoplasmic sperm injection, comparison between 151
when intrauterine insemination has failed 125
laboratory procedures after stimulation 127–31
long-term complications in the child 152
in the mother 153
male infertility 78–9, 81
myomas, uterine 30
ovarian reserve, diminished 59, 61, 62, 63, 64–9
ovarian torsion 149
polycystic ovary syndrome 55–6, 57
polyps, endometrial 33
poor responders 64, 67, 68, 69
pregnancy complications 152
preimplantation genetic diagnosis 155, 157, 159, 161, 162
protocols 64–6
smoking 3
stress, psychological 150
tubal surgery versus 23–4
unexplained infertility 86, 88
in-vitro maturation of ovarian tissue 170
Ireland, Republic of 178
Israel 176, 177, 178, 179
Italy 178, 179
Japan 176, 177, 178
kallikrein 75
Kallman syndrome
females 49, 106
males 76
kinin-enhancing drugs 75
Korea 176
lanreotide 95
laparoscopic oophoropexy 171
laparoscopic ovarian drilling (LOD) 56–7
laparoscopy 9
endometriosis
diagnosis 41–2
treatment 45, 46, 47
fallopian tube assessment 10, 11, 18, 19, 24, 84–5
before intrauterine insemination 116
myomectomy 33
pelvic peritoneum evaluation 13
unexplained infertility 84–5
laser-assisted immobilized sperm selection (LAISS) 79
leiomyosis, uterine 30–3, 36
lesbian couples 180, 181
letrozole
adverse effects and safety concerns 110–11
dose, optimal 110
endometriosis 44
fertility preservation 166
intrauterine insemination 117
ovarian reserve, diminished 68, 69
ovulation induction 108, 109, 110
polycystic ovary syndrome 56, 109
leukemia 169
leuprolide acetate 64, 65, 140
levothyroxine 99
liver dysfunction 148
long agonist protocol, IVF 64, 66
low birth weight (LBW) 151, 152
long-term complications 152
multiple gestation 146
ovarian hyperstimulation syndrome 148
low-dose long agonist protocol, IVF 64, 66
lutentizing hormone (LH) intraperitoneal insemination 116
ovulation induction 105–6
physiological basis of 103, 104
lymphatic and vascular metastasis theory, endometriosis 39
lymphoma 168, 169
magnetic resonance imaging (MRI)
amenorrhea; oligomenorrhea metabolic syndrome 52, 53
metaplasia II (MII) oocyte cryopreservation 166
metastatic cancer 169, 170, 171
metformin 55–6
methimazole 97
metroplasty, hysteroscopic 29, 36
microdose flare protocol, IVF 65–6
microinjection, IVF 129–30
microsurgical epididymal sperm aspiration (MESA) 79–80
microsurgical testicular sperm extraction 80
Middle East 176, 179
miscarriage 148
monogenic disorders, preimplantation genetic diagnosis for 156–7
Montenegro 179
mouse oocyte activation test (MOAT) 79
endometriosis 41
hyperprolactinaemia and prolactinomas 91, 92, 93
MRI-guided focused ultrasound (MRgFUS) 32, 36
uterus evaluation 13, 27, 30
Malaysia 176
male infertility 71, 81
evaluation 15–16, 71–4
intrauterine insemination 114–15, 118
treatment 74–81
malnutrition 152
Marfan syndrome 157
medgestrol acetate 43
medroxyprogesterone acetate 43, 45
melanoma 153
menopausal transition 60
menopause 60
egg donation 135
physiological basis 103
premature 49–50
menstruation
BMI and 54
history 9
irregular 14–15
physiological basis of ovulation 102–4
retrograde 38
metabolic syndrome 52, 53
metaplasia II (MII) oocyte cryopreservation 166
metastatic cancer 169, 170, 171
metformin 55–6
methimazole 97
metroplasty, hysteroscopic 29, 36
microdose flare protocol, IVF 65–6
microinjection, IVF 129–30
microsurgical epididymal sperm aspiration (MESA) 79–80
microsurgical testicular sperm extraction 80
Middle East 176, 179
miscarriage 148
monogenic disorders, preimplantation genetic diagnosis for 156–7
Montenegro 179
mouse oocyte activation test (MOAT) 79
endometriosis 41
hyperprolactinaemia and prolactinomas 91, 92, 93
MRI-guided focused ultrasound (MRgFUS) 32, 36
uterus evaluation 13, 27, 30
Malaysia 176
male infertility 71, 81
evaluation 15–16, 71–4
intrauterine insemination 114–15, 118
treatment 74–81
malnutrition 152
Marfan syndrome 157
medgestrol acetate 43
medroxyprogesterone acetate 43, 45
melanoma 153
menopausal transition 60
menopause 60
egg donation 135
physiological basis 103
premature 49–50
menstruation
BMI and 54
history 9
irregular 14–15
physiological basis of ovulation 102–4
retrograde 38
metabolic syndrome 52, 53
metaplasia II (MII) oocyte cryopreservation 166
metastatic cancer 169, 170, 171
metformin 55–6
methimazole 97
metroplasty, hysteroscopic 29, 36
microdose flare protocol, IVF 65–6
microinjection, IVF 129–30
microsurgical epididymal sperm aspiration (MESA) 79–80
microsurgical testicular sperm extraction 80
Middle East 176, 179
miscarriage 148
monogenic disorders, preimplantation genetic diagnosis for 156–7
Montenegro 179
mouse oocyte activation test (MOAT) 79
MRI see magnetic resonance imaging
müllerian anomalies 27–30, 38
multiple displacement amplification (MDA), preimplantation genetic screening 160
multiple gestation 146–7
aromatase inhibitors 109, 110, 111
clofibrate citrate 107
intrauterine insemination 124
regulation of infertility treatment 180
surrogacy 144
multiple sclerosis 76
myocardial infarction 146
myolysis 32
myomas, uterine 30–3, 36
myomectomy 30–1, 32–3, 36
National Center for Biotechnology Information (NCBI) 161
National Institute for Health and Clinical Excellence (NICE) 116
National Institutes of Health (NIH) 1, 50
natural cycle IVF 66
crozoospermia 79
Netherlands 176, 179
neural tube defects 2
neurodevelopmental delay 146
non-Hodgkin lymphoma 168
nonobstructive azoospermia (NOA) 80–1
nonsteroidal anti-inflammatory drugs (NSAIDs) 42–3
norethindrone 43, 44
North America, infertility treatment in 181
outcome monitoring and success rates 181
regulation 179, 180–1
reimbursement 177–8
utilization and availability 176, 177
Norway 179, 180
nuclear maturity, assessment of 129
obesity see overweight and obesity
obstructive azoospermia 79–80
octreotide 95
oligomenorrhea 48
ovulation induction 107
polycystic ovary syndrome 51
oligozoospermia 71
chromosomal abnormalities 74
investigations 72
treatment 74–5
oocytes
assessment, IVF 131
cryopreservation
age factors 3
egg donation 138
fertility preservation 111, 165, 166–8, 172–3
donation see egg and embryo donation
oocyte pick-up (OPU) 151
oophoropexy (ovarian transposition) 149, 171, 172
oral contraceptives
diminished ovarian reserve treatment 63, 65–6
egg donation 140
endometriosis treatment 43
oral glucose tolerance test (OGTT) 52, 95, 96
orchitis 72
orthotopic transplantation of ovarian tissue 168–9
ovarian anovulation 49–50
ovarian cancer 153
ovarian cyst rupture 150
ovarian drilling, laparoscopic (LOD)
polycystic ovary syndrome 56–7
ovarian failure chemotherapy 172
premature 49–50
Turner syndrome 53
ovarian follicle pool 59, 60
ovarian hyperstimulation see ovulation induction
ovarian hyperstimulation syndrome (OHSS) 147–8
aromatase inhibitors 109
egg donation 138, 141
intrauterine insemination 124–5
metformin 55–6
polycystic ovary syndrome 55–6, 57
risk factors 147
thromboembolism 150
unexplained infertility 88
ovarian physiology 59
ovarian reserve
age factors 14, 60, 61
diminished 59, 69–70
diagnosis 60–3
oocyte quantity versus quality 60
treatment 63–9
testing 13–15
egg donation 138
ovarian stimulation see ovulation induction
ovarian tissue
cryopreservation 165, 168–70, 172, 173
ovarian torsion 149
ovarian transposition (oophoropexy) 149, 171, 172
ovarian ultrasonography 10
ovarian volume measurement 63
ovaries, cryopreservation of whole 170–1, 173
overweight and obesity
BMI as factor affecting fertility 2, 6, 86
polycystic ovary syndrome 53, 54
ovulation
assessment 9–10
unexplained infertility 84
disorders 48
classification 48, 49
diagnosis 48–54
intrauterine insemination 115
treatment 54–7
see also anovulation
physiological basis of 102–4
ovulation detection test 9
ovulation induction 102, 112
aromatase inhibitors 108–12
breast cancer patients 165
clomiphene citrate 105–8
injectable gonadotropin preparations 104–5
intrauterine insemination 116–18
levothyroxine requirements, hypothyroidism 99
side effects 150
unexplained infertility 87–8
pain
egg retrieval 151
endometriosis 42–4
intrauterine insemination 123
pegvisomant 95
pelvic inflammatory disease (PID) 12, 21
chlamydia 12, 21
intrauterine insemination 123
tubal factor infertility 18, 20, 21
pelvic injuries caused by egg retrieval 151
pelvic peritoneum 13
pelvic sarcomas 171
pelvic transplantation of ovarian tissue 168–9
penile vibrostimulation 76
percutaneous epididymal sperm aspiration (PESA) 79–80
perinatal mortality 152
peritoneal environment, immunologic dysfunction in the 39–40
phenylpropanalamine 76
physical examination of female 8–9, 40, 84
of male 72
pinopods 140
pituitary anovulation 49
pituitary disorders 90
neoplasms 91–4
placental abruption 148, 152
placenta previa 152
polycystic ovary syndrome (PCOS)
aromatase inhibitors 109, 110, 112
clinical features 51–3
and Cushing syndrome, phenotypic overlap between 100
ovulation induction 110, 112, 116
ovulatory disorders 48, 50–3
treatment 54–7, 109
ultrasoundography 10
weight reduction 2, 54
polymerase chain reaction (PCR), preimplantation genetic diagnosis 156, 157–8
polypectomy 33–4, 36
polyps 11, 12, 33–4, 36
Portugal 178, 179
postcoital test (PCT) 13, 84, 114
postejaculatory urinatalysis 16
postpartum hemorrhage 146
povidone iodine 123
preconceptual counseling see counseling: preconceptual
prednisolone 66, 77
pre-eclampsia 146, 152
pregnancy complications 151–2
pregnancy-induced hypertension (PIH) 148
preimplantation genetic diagnosis (PGD) 155, 162
advances and future perspectives 161–2
aneuploidy screening using FISH 159
chromosomal rearrangements 158–9
embryo biopsy 155–6
ethical aspects 160–1
HLA typing 158
monogenic disorders 156–7
polymerase chain reaction (PCR) methods, pitfalls 157–8
regulation 179
whole-genome amplification, pitfalls 160
whole-genome screening for aneuploidy 160
preimplantation genetic screening (PGS) 155, 159–60, 161
premature delivery see preterm delivery
premature menopause 49–50
premature ovarian failure 49–50
preservation of fertility see fertility preservation
preterm delivery 151, 152
multiple gestation 146
ovarian hyperstimulation syndrome 148
primary testicular failure 80
progesterone
egg donation 139–40, 141
implantation window 139–40, 141
ovulation, physiological basis of 103–4
progestins, endometriosis treatment 43
prolactin 92
“big” and “big big/macroprolactin” 92
regulation of release 90
unexplained infertility 85
prolactinomas 49, 101
brain imaging 91–2
therapy 92–4
propylthiouracil (PTU) 97
pulmonary edema 146
pulmonary embolism 148
radiotherapy
acromegaly 95, 96
fertility preservation 164, 165, 173
hyperprolactinaemia and prolactinomas 93–4
hypogonadotropic hypogonadism 49
rational infertility treatments 175
regulation of infertility treatment 178–81
reimbursement of infertility treatment 177–8
renal failure 148
reproductive potential tests 3
retrograde ejaculation 76–7, 115–16
retrograde menstruation theory, endometriosis 38
rubella 85
saline infusion sonography (SIS) see sonohysterography
salpingectomy for tubal occlusion 22–3
salpingitis isthmic nodosum (SIN) 11
salpingography 72
salpingoophorectomy, bilateral 45
salpingoscopy 12, 21
salpingostomy 22
same-sex couples 135, 144, 180, 181
Sampson’s theory, endometriosis 38
Scandinavia 176, 177, 178, 180
scrotalgia 72
scrotal ultrasonography 16, 72
selective salpingography and transcervical tubal cannulation 72
semen analysis 9, 16, 71, 73
unexplained infertility 84
WHO reference values 16, 71, 72, 118–19, 128
collection 119
preparation 118–19, 128
see also sperm
sensitization, and intrauterine insemination 123
septate uterus 29, 36
Serbia 179
serial ultrasonography 10
serum endocrinologic assays 14
serum progesterone testing 10
sex hormone binding globulin (SHBG) 98
sexual dysfunction 115
Sheehan syndrome 49, 106
single nucleotide polymorphism (SNP) assays 160, 161–2
single women, treatment of 179, 180
sleep apnea 53
slow cooling protocol oocyte cryopreservation 167
ovarian tissue cryopreservation 168
smoking 3–4, 5, 6, 86
male infertility 74
social sexing 161
Society for Assisted Reproductive Technology (SART) egg donation 137
embryo transfer 180–1
outcome monitoring, infertility treatment 181
ovarian reserve, diminished 61
somatostatin agonists 95
sonography 3
sonohysterography (SHG, saline infusion sonography) 12
polyps, endometrial 33
preoperative 20–1
rumin factor infertility 20
uterus evaluation 12–13, 27
South America 179
South Korea 176
Spain 178, 179
sperm autoimmunity 77
concentration 3
donation 81
infection transmission 120
regulation 179
motility 3, 79
surgical recovery 79–81
see also semen
spinal cord injury, and ejaculatory failure 76, 116
spotting, after intrauterine insemination 123
stem cell theory, endometriosis 39
stereotactic gamma knife radiosurgery 94, 96
sterilization reversal 23, 77, 79
“stop” IVF protocol 65
stress, psychological 150
surrogacy 135, 144
regulations 179–80
Sweden 146, 179, 180
swim-up technique, semen preparation 119, 128, 129
Switzerland 178, 179
symptomatic infertility treatments 175
syncpe, and intrauterine insemination 123
synechiae, uterine 11–12
syphilis 85
systemic lupus erythematosus (SLE) 164, 172
T₃ (triiodothyronine) 96, 97
T₄ (thyroxine) 96, 97
tamoxifen breast cancer 111, 165–6
fertility preservation 165–6
male infertility 74
pharmacokinetics 105
cystic ovary syndrome 55
testicular aspiration 79, 80
testicular biopsy 79, 80
testicular failure, primary 80
testicular feminization 53–4
testicular mapping 80
testicular mass, palpable 72
testicular sperm extraction (TSE) 80
testicular tumors 72
testosterone, transdermal 67
thromboembolism (TE) 146, 150
thrombophilia, inherited 136
thyroid cancer 153
thyroid disorders 96–9, 101
thyroid hormone production, regulation of 96
thyroid stimulating hormone (TSH) 96, 97, 98–9
unexplained infertility 85
thyrotoxicosis (“thyroid storm”) 96–7
thyrotropin-releasing hormone (TRH) 96, 98–9
thyroxine (T₄) 96, 97
thyroxin-binding globulin (TBG) 97
timed intercourse (TI) 86–7, 121
time to pregnancy (TTP) 1
total abdominal hysterectomy 45
tourism, reproductive 178
transabdominal ultrasonography 52
transcervical tubal cannulation 72
transdermal testosterone 67
trans-sphenoidal surgery 93, 95
transuterotubal intrafallopian insemination 122
transvaginal intrafallopian insemination 122
transvaginal ultrasonography adenomyosis 35
ectopic pregnancy 148
egg donation 138, 140, 141
endometriosis 41
ovulation assessment 10
cystic ovary syndrome 52
polyps, endometrial 33
tubal factor infertility 20
uterus evaluation 12, 27
thyroid hormone (T₄) 96, 97
tubal cannulation, transcervical 72
tubal disease distal 18–19, 22
proximal 19, 22
tubal infertility see under fallopian tubes
tubal pregnancy 148
tubal reanastamosis 23
tuberculosis, genital 34
tubocornual anastamosis 22
Turkey 178, 179
Turner syndrome 53
twins see multiple gestation
twin-to-twin transfusion syndrome 147
two-cell, two-gonadotropin theory of ovulation 102
Ukraine 178, 179
ultrasoundography Doppler ultrasound of the testis 80
MRI-guided focused ultrasound (MRgFUS) 32, 36
cystic ovary syndrome 51–2
intrauterine insemination 116
ovarian 10
scrotal 16, 72
serial 10
transabdominal 52
transvaginal see transvaginal ultrasonography
unexplained infertility 85
underweight 1, 2
unexplained infertility 83, 88
assisted reproductive technologies 87–8
basic fertility work-up 83–5
Intrauterine insemination 115, 116, 117, 125
management 86–7
prognosis 85–6
unicornuate uterus 29–30, 36
United Kingdom
egg donation 139, 143, 179
outcome monitoring of infertility treatment 181
regulation of infertility treatment 179
reimbursement of infertility treatment 178
utilization and availability of infertility treatment 177
United States Department of Agriculture (USDA) 2, 6
United States of America
egg donation 135, 137, 139, 143–4
embryo cryopreservation 165
outcome monitoring of infertility treatment 181
regulation of infertility treatment 179, 180, 181
reimbursement of infertility treatment 177
surrogacy 135, 144
utilization and availability of infertility treatment 176, 177
United States Public Health Service (USPHS) 3
United States Surgeon General 5
ureteral injuries following egg retrieval 151
urinalysis, postejaculatory 16
uterine artery embolization (UAE) 32
uterine infertility 26, 36
acquired anomalies 30–6
congenital anomalies 27–30
uterovaginal development 28
uterus, evaluation 12–13, 26–7
utilization of infertility treatment 176–7
vaginal syndrome 151
vaginal cancer 171
vaginismus 115
vanishing twin syndrome 152
varicocele treatment 74, 75
vas deferens, congenital absence of the 74
vasectomy reversal 77, 79
vasoepididymostomy 77, 79
vasovagal response, intrauterine insemination 123
venous thromboembolism 146, 150
vibrostimulation, penile 76
vitrification
embryo 161
IVF 133, 134
oocyte cryopreservation 167
ovarian tissue cryopreservation 168
von Willebrand disease 141
waiting lists 178
weight, as factor affecting fertility 1–2, 5, 6
weight loss to improve fertility 2, 6
polycystic ovary syndrome 2, 54
unexplained infertility 86
ovulatory disorders resulting from 48, 51
whole-genome screening 158, 160
World Health Organization (WHO)
BMI 1
male infertility 71–2
ovulatory disorders 48, 49, 104
semen analysis 16, 71, 72, 118–19, 128
xenotransplantation of ovarian tissue 169–70
zuclomiphene 105